November 02, 2018 Nordic Nanovector Announces First Patient Dosed in Archer-1 Trial of Betalutin® plus Rituximab in Follicular Lymphoma
November 01, 2018 Nordic Nanovector: Promising results from preclinical studies with a novel CD37-targeted alpha therapy for B-cell tumours to be presented at ASH
November 01, 2018 Nordic Nanovector highlights promising clinical results from Phase 1/2 trial of Betalutin® in relapsed/refractory indolent non-Hodgkin’s lymphoma
November 01, 2018 Oncopeptides to present updated data from the two ongoing trials ANCHOR and HORIZON in patients with RRMM at ASH in December 2018